0001570562-23-000117.txt : 20231208
0001570562-23-000117.hdr.sgml : 20231208
20231208181559
ACCESSION NUMBER: 0001570562-23-000117
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231206
FILED AS OF DATE: 20231208
DATE AS OF CHANGE: 20231208
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MOATAZEDI DAVID
CENTRAL INDEX KEY: 0001700836
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38381
FILM NUMBER: 231476591
MAIL ADDRESS:
STREET 1: C/O OBALON THERAPEUTICS, INC.
STREET 2: 5421 AVENIDA ENCINAS, SUITE F
CITY: CARLSBAD
STATE: CA
ZIP: 92008
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Evolus, Inc.
CENTRAL INDEX KEY: 0001570562
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 461385614
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 520 NEWPORT CENTER DRIVE
STREET 2: SUITE 1200
CITY: NEWPORT BEACH
STATE: CA
ZIP: 92660
BUSINESS PHONE: (949) 284-4555
MAIL ADDRESS:
STREET 1: 520 NEWPORT CENTER DRIVE
STREET 2: SUITE 1200
CITY: NEWPORT BEACH
STATE: CA
ZIP: 92660
4
1
wk-form4_1702077349.xml
FORM 4
X0508
4
2023-12-06
0
0001570562
Evolus, Inc.
EOLS
0001700836
MOATAZEDI DAVID
520 NEWPORT CENTER DR.
SUITE 1200
NEWPORT BEACH
CA
92660
1
1
0
0
See Remarks
0
Common Stock
2023-12-06
4
S
0
51348
10.0859
D
635244
D
Common Stock
2023-12-08
4
S
0
31300
9.7286
D
603944
D
The shares were sold in multiple trades at prices ranging from $10.00 to $10.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The shares were sold in multiple trades at prices ranging from $9.61 to $9.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
President and Chief Executive Officer
/s/ Jeffrey J. Plumer, as attorney-in-fact for David Moatazedi
2023-12-08